• Patients & Families
• Education
• Research
• Community

• Referring Physicians
• Find a Physician
• Departments & Centers
• About URMC

• Libraries
• Alumni
• Giving

URMC  » CFAR » Funding Opportunities

• Home
• About Us
• Core Facilities & Services
• Mentoring & Training
• Research
• Funding Opportunities
  • Pilot Program
  • Micro Grants Program
  • Supplement Award Program
  • Vouchers and Other Funding
• News
• Events
• Community Outreach

Supplement Award Program

HIV/AIDS Related Malignancies

Stimulates research on HIV-associated malignancies to foster multidisciplinary collaborations between Cancer and CFAR investigators by supporting one-year pilot research projects in HIV-associated malignancies. Pilot studies may include basic, translational, and clinical research on the etiology, pathogenesis, prevention, and management of AIDS-defining and non-AIDS-defining malignancies.

HIV-TB Co-infection

Supports a broad range of highly innovative research on: the alterations in HIV pathogenesis and the host immune response in the setting of TB co-infection; TB related immune reconstitution inflammatory syndrome (IRIS); the effect of TB on HIV clinical disease progression, and changes in latent TB activation and/or active disease progression in the setting of antiretroviral therapy.

Nanotechnology and HIV

Supports a broad range of highly innovative, nanotechnology-based research projects in the field of HIV and HIV-related co-infections such as tuberculosis and hepatitis. Technologies to prevent transmission or acquisition of HIV, improve treatment of HIV and its co-infections, and ultimately cure HIV infection are of particular interest.

HIV and Aging

The goal of this funding opportunity is to improve medical outcomes, functional status and quality of life in older patients with HIV/AIDS through improved understanding of interactions among aging processes, HIV viral infection, treatment effects and toxicities, and multiple morbidities commonly occurring in older persons.

HIV Vaccine Discovery

Supports a broad range of highly innovative research in HIV vaccine discovery, including novel assay/technology development, immunology, virology, cellular and structural biology and host genetics, and novel concepts and approaches applicable to the design of an effective prophylactic HIV vaccine.

Outside the Box AIDS Vaccine Award

Stimulates the discovery, design and preclinical evaluation of highly innovative approaches that could provide long term protection from acquiring HIV infection. Applicants are expected to explore novel hypotheses or address difficult problems, the solutions to which could have a significant impact on finding methods to interrupt HIV transmission.

Learn more about current CFAR Supplement Opportunities.

Active Supplement Awards

Krupa Shah,
Medicine, Geriatrics

Physical Frailty and Sarcopenia in HIV/AIDS Older Adults

Andrea Sant,
Center for Vaccine Biology and Immunology

Design of optimal multi-epitope vaccines to elicit CD4 T cell immunity to HIV (HIV Vaccine Discovery)

Danielle Benoit,
Biomedical Engineering

Using Nanotechnology to Improve Mucosal Delivery of Candidate HIV-1 Vaccines (Nanotechnology and HIV)

Steve Gill,
Microbiology and Immunology

Oral Cavity Squamous Cell Carcinoma and Oral Microbiota in HIV-Positive Individuals (HIV/AIDS Related Malignancies)

Sanjay Maggirwar,
Microbiology and Immunology

CD40L connects Aging, HIV-1 and Malignancy (HIV/AIDS Related Malignancies)